Tumor necrosis factor receptor superfamily member 1A · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Tumor necrosis factor receptor superfamily member 1A shows clinical signal disease relevance led by respiratory system disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P19438. Start with respiratory system disease, then reuse UniProt P19438 as the stable protein anchor across project notes and exports.
Start with respiratory system disease, then reuse UniProt P19438 as the stable protein anchor across project notes and exports.
Tumor necrosis factor receptor superfamily member 1A shows clinical signal disease relevance led by respiratory system disease. 1 linked drug remains visible in the same block.
Start review with respiratory system disease because it currently carries clinical signal support. Linked drugs include GSK-1995057. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTumor necrosis factor receptor superfamily member 1A
Review this target as Tumor necrosis factor receptor superfamily member 1A, mapped to UniProt P19438. Sequence length is 455 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tumor necrosis factor receptor superfamily member 1A as ChEMBL target CHEMBL3378, mapped to UniProt P19438. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tumor necrosis factor receptor superfamily member 1A is the right protein anchor across sources, using UniProt P19438 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why respiratory system disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tumor necrosis factor receptor superfamily member 1A |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P19438 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tumor necrosis factor receptor superfamily member 1A |
| UniProt Accession | P19438 |
| Component Type | Protein |
| Sequence Length | 455 aa |
Tumor necrosis factor receptor superfamily member 1A
Review this target as Tumor necrosis factor receptor superfamily member 1A, mapped to UniProt P19438. Sequence length is 455 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tumor necrosis factor receptor superfamily member 1A shows clinical signal disease relevance led by respiratory system disease.
Start review with respiratory system disease because it currently carries clinical signal support. Linked drugs include GSK-1995057. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL359346 | 6.89 | IC50 | 130.0 | Preclinical |
| CHEMBL357092 | 6.85 | IC50 | 140.0 | Preclinical |
| CHEMBL150292 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL356012 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL151203 | 6.55 | IC50 | 280.0 | Preclinical |
| CHEMBL356830 | 6.55 | IC50 | 280.0 | Preclinical |
| CHEMBL150886 | 6.52 | IC50 | 300.0 | Preclinical |
| CHEMBL423208 | 6.51 | IC50 | 310.0 | Preclinical |
| CHEMBL146955 | 6.5 | IC50 | 320.0 | Preclinical |
| CHEMBL151686 | 6.41 | IC50 | 390.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 17 | 40 | 5.8 |
| cell-based format | 3 | 1 | 6.1 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 73 | 5.4 |